Literature DB >> 15349729

[Whole-body tumor staging: MRI or FDG-PET/CT?].

G Antoch1, F M Vogt, A Bockisch, S G Ruehm.   

Abstract

Technical innovations such as the availability of movable patient platforms and the introduction of 32-channel systems have made whole-body MRI for tumor staging feasible. In addition, the development of dual-modality PET/CT systems offers the opportunity to perform anatometabolic tumor staging with whole-body coverage in a single session. Based on an increase in patient survival when applying a stage-adapted therapy in different malignant diseases the relevant question relates to the accuracies of whole-body MRI and whole-body PET/CT for TNM staging. This review article addresses whole-body tumor staging with MRI and FDG-PET/CT with special emphasis on diagnostic accuracies for staging different malignant diseases.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15349729     DOI： 10.1007/s00117-004-1093-x

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


  30 in total

1.  Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement.

Authors:  Sven C A Michel; Thomas M Keller; Johannes M Fröhlich; Daniel Fink; Rosmarie Caduff; Burkhardt Seifert; Borut Marincek; Rahel A Kubik-Huch
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

2.  Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy.

Authors:  C A Staples; N L Müller; R R Miller; K G Evans; B Nelems
Journal:  Radiology       Date:  1988-05       Impact factor: 11.105

3.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

Authors:  H E Daldrup-Link; C Franzius; T M Link; D Laukamp; J Sciuk; H Jürgens; O Schober; E J Rummeny
Journal:  AJR Am J Roentgenol       Date:  2001-07       Impact factor: 3.959

Review 4.  Role of magnetic resonance imaging in the staging of gastrointestinal neoplasms.

Authors:  R Ferraris; A del Piano; J J Galli
Journal:  Semin Surg Oncol       Date:  2001-03

5.  Liver lesion detection, characterization, and effect on patient management: comparison of single-phase spiral CT and current MR techniques.

Authors:  R C Semelka; S Worawattanakul; N L Kelekis; G John; J T Woosley; M Graham; W G Cance
Journal:  J Magn Reson Imaging       Date:  1997 Nov-Dec       Impact factor: 4.813

6.  FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging.

Authors:  C Franzius; H E Daldrup-Link; A Wagner-Bohn; J Sciuk; W L Heindel; H Jürgens; O Schober
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

7.  Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma.

Authors:  A Gdeedo; P Van Schil; B Corthouts; F Van Mieghem; J Van Meerbeeck; E Van Marck
Journal:  Eur J Cardiothorac Surg       Date:  1997-08       Impact factor: 4.191

8.  The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.

Authors:  L James Wudel; Dominique Delbeke; David Morris; Michael Rice; Mary Kay Washington; Yu Shyr; C Wright Pinson; William C Chapman
Journal:  Am Surg       Date:  2003-02       Impact factor: 0.688

9.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

10.  Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.

Authors:  Gerald Antoch; Florian M Vogt; Lutz S Freudenberg; Fridun Nazaradeh; Susanne C Goehde; Jörg Barkhausen; Gerlinde Dahmen; Andreas Bockisch; Jörg F Debatin; Stefan G Ruehm
Journal:  JAMA       Date:  2003-12-24       Impact factor: 56.272
View more
  7 in total

Review 1.  [Whole body MRI--diagnostic strategy of the future?].

Authors:  M Goyen; H-P Schlemmer
Journal:  Radiologe       Date:  2007-10       Impact factor: 0.635

2.  [Cost considerations for whole-body MRI and PET/CT as part of oncologic staging].

Authors:  C Plathow; M Walz; M P Lichy; P Aschoff; C Pfannenberg; H Bock; S M Eschmann; C D Claussen; H P Schlemmer
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

3.  MRI of respiratory dynamics with 2D steady-state free-precession and 2D gradient echo sequences at 1.5 and 3 Tesla: an observer preference study.

Authors:  M Fabel; B J Wintersperger; O Dietrich; M Eichinger; C Fink; M Puderbach; H-U Kauczor; S O Schoenberg; J Biederer
Journal:  Eur Radiol       Date:  2008-09-06       Impact factor: 5.315

4.  [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].

Authors:  C Pfannenberg; N Schwenzer
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

Review 5.  [Automated procedure for volumetric measurement of metastases: estimation of tumor burden].

Authors:  M Fabel; H Bolte
Journal:  Radiologe       Date:  2008-09       Impact factor: 0.635

6.  Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development.

Authors:  Till A Heusner; Steffen Hahn; Monia E Hamami; Un-Hi Kim; Rilana Baumeister; Michael Forsting; Alexander Stahl; Andreas Bockisch; Gerald Antoch
Journal:  Eur Radiol       Date:  2009-05-05       Impact factor: 5.315

7.  Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development?

Authors:  Till A Heusner; Steffen Hahn; Monia E Hamami; Svenja Kögel; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander R Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-21       Impact factor: 9.236
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.